Alzheimer’s Disease is the most common cause of dementia. Dementia describing a specific set of symptoms such as memory loss, difficulties with problem-solving, language or simply thinking. As the disease progresses, proteins build up in the brain to form structures called ‘plaques’. Eventually there is a break between the nerve cells resulting the death of the cells and a loss of brain tissue. ending in a lack of motor skills. Although progression can vary, typically after diagnosis life expectancy is around three to nine years. Fewer than 3% of people live more than fourteen years.
Management
Medications, psychological intervention and care-giving are all available to AD patients. there are currently 5 different medications on offer for AD each have different results and side affects.
FDA clearance of the first Alzheimer's blood test marks a significant step toward earlier, more straightforward diagnosis—potentially improving care for adults with memory concerns.
FDA clearance of the first Alzheimer's blood test marks a significant step toward earlier, more straightforward diagnosis—potentially improving care for adults with memory concerns.
A new study led by researchers at Karolinska Institutet has shown that specific blood biomarkers could predict the onset of dementia, including Alzheimer's disease, up to ten years before an actual diagnosis in older adults living independently.
For nearly a century, medical experts have known that individuals who suffer brain trauma, such as traumatic brain injury (TBI), are at an increased risk of developing dementia later in life.
A second groundbreaking drug for Alzheimer's disease has been rejected for widespread use by the NHS in England; according to the drugs spending watchdog, the drug known as Donanemab does not offer sufficient value for money.
Dhivya Venkat, CEO & Co-Founder of Esya Inc., discusses the urgent need for integrating innovative diagnostics and therapies into the NHS in order to improve dementia care and diagnosis.
